6 results
The objective of the study is to assess the efficacy and safety of Alirocumab in patients with heterozygote familial hypercholesterolemia whose LDL-C level is higher than or equal to 160 mg/dL (4.14 mmol/L) on maximally tolerated statin therapy with…
This study is therefore aimed at quantifying the relative contribution of the two major receptor systems involved in S(+)-ketamine and methadone induced analgesia and side effects (respiratory depression, sedation, miosis).
The aim of this study is to demonstrate that procedural sedation with propofol and esketamine is more effective and will result in less cardiopulmonary depression than sedation with propofol and the opioid alfentanil. Less side effects should also…
Primary objective* To assess the long-term safety of alirocumab when added to currently available lipid-modifying drug therapy in patients with heterozygous familial hypercholesterolemia (heFH) who have completed one of the following studies:…
In the present study, we set out to evaluate arterial wall inflammation in patients at increased CV-risk with statin-associated muscle symptoms (SAMS), precluding effective statin therapy. Following twelve weeks of treatment with PCSK9-Ab, the…
To assess arterial wall inflammation, measured with 18F-FDG PET/CT scan, in patients with intermediate and severe FH phenotype, as well as the change in arterial wall inflammation following PCSK9 inhibition.